Last reviewed · How we verify
NCT05025527
Biparametric MRI in Prostate Cancer Screening: a Noninferior Randomized Controlled Study
NA trial testing biparametric MRI (bpMRI) in Prostate Cancer in 500 participants. Status unknown.
1 December 2024
Quick facts
| Lead sponsor | Shanghai East Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | screening |
| Enrollment | 500 |
| Start date | 1 December 2022 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- biparametric MRI (bpMRI)
- Prostate cancer antigen (PSA)
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Shanghai East Hospital
Who can join
Adults 50 to 80, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single centre non-inferiority randomized controlled trial in comparison of the bpMRI between the traditional pathway in prostate cancer screening
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05025527
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Shanghai East Hospital trials
Trials by the same sponsor.
- NCT07519161 — Pharmacological Intervention to Prevent NOAF After TAVR · NA · not yet recruiting
- NCT07516223 — MRI-Assisted Guidance for Non-Essential Tissue Sampling · NA · not yet recruiting
- NCT07279259 — Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management · Phase 2 · recruiting
- NCT07294495 — Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Tr · NA · not yet recruiting
- NCT07290816 — Effect of Non-invasive Neuromodulation on the Quality of Intestinal Cleansing · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05025527 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai East Hospital
- Last refreshed: 28 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05025527.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing